X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7219) 7219
Magazine Article (28) 28
Book Chapter (11) 11
Newsletter (9) 9
Dissertation (7) 7
Book / eBook (2) 2
Newspaper Article (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5759) 5759
enterobacteriaceae (2791) 2791
male (2619) 2619
infectious diseases (2610) 2610
female (2575) 2575
enterobacteriaceae infections - drug therapy (2509) 2509
microbiology (2486) 2486
anti-bacterial agents - therapeutic use (2072) 2072
microbial sensitivity tests (2022) 2022
anti-bacterial agents - pharmacology (1966) 1966
enterobacteriaceae - drug effects (1822) 1822
middle aged (1786) 1786
aged (1586) 1586
adult (1558) 1558
enterobacteriaceae infections - microbiology (1534) 1534
pharmacology & pharmacy (1331) 1331
antibiotics (1266) 1266
infections (1256) 1256
escherichia-coli (1254) 1254
bacteria (1201) 1201
klebsiella-pneumoniae (1085) 1085
epidemiology (1031) 1031
enterobacteriaceae - isolation & purification (1019) 1019
drug resistance (939) 939
beta-lactamases - genetics (892) 892
risk factors (828) 828
animals (805) 805
beta-lactamases - metabolism (797) 797
prevalence (759) 759
drug resistance, bacterial (757) 757
adolescent (750) 750
health aspects (727) 727
resistance (727) 727
escherichia coli - drug effects (721) 721
drug resistance in microorganisms (701) 701
urinary tract infections - drug therapy (676) 676
research (672) 672
enterobacteriaceae infections - epidemiology (671) 671
antimicrobial resistance (663) 663
aged, 80 and over (650) 650
hospitals (649) 649
child (647) 647
mortality (633) 633
drug resistance, multiple, bacterial (628) 628
klebsiella pneumoniae - drug effects (626) 626
retrospective studies (616) 616
e coli (602) 602
risk-factors (600) 600
bacteremia (591) 591
antimicrobial agents (575) 575
escherichia coli (574) 574
drug resistance, microbial (570) 570
enterobacteriaceae - enzymology (555) 555
klebsiella infections - drug therapy (554) 554
treatment outcome (538) 538
cross infection - microbiology (536) 536
immunology (532) 532
gram-negative bacteria (527) 527
infant (524) 524
infectious disease (518) 518
child, preschool (504) 504
escherichia coli infections - drug therapy (499) 499
genes (482) 482
urinary tract infections - microbiology (478) 478
beta lactamases (476) 476
infant, newborn (473) 473
infection (471) 471
pathogens (470) 470
bacterial infections - drug therapy (468) 468
klebsiella infections - microbiology (466) 466
biochemical phenomena, metabolism, and nutrition (459) 459
carbapenems - pharmacology (453) 453
research article (448) 448
pneumonia (447) 447
emergence (443) 443
escherichia coli - isolation & purification (443) 443
bacterial infections and mycoses (442) 442
enterobacteriaceae - genetics (430) 430
beta-lactamases - biosynthesis (429) 429
beta-lactam resistance (427) 427
pseudomonas infections - drug therapy (424) 424
analysis (420) 420
cross infection - drug therapy (419) 419
klebsiella pneumoniae - isolation & purification (419) 419
antibiotic resistance (415) 415
bacterial proteins - genetics (415) 415
bacteremia - microbiology (413) 413
pseudomonas-aeruginosa (408) 408
nosocomial infections (405) 405
escherichia coli infections - microbiology (404) 404
medicine (404) 404
carbapenemase (403) 403
medicine, general & internal (392) 392
cephalosporins - therapeutic use (386) 386
surveillance (381) 381
klebsiella (380) 380
pseudomonas aeruginosa - drug effects (380) 380
susceptibility (375) 375
klebsiella pneumoniae (372) 372
enterobacter (371) 371
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6688) 6688
French (183) 183
Spanish (141) 141
German (123) 123
Russian (73) 73
Portuguese (54) 54
Japanese (53) 53
Italian (47) 47
Polish (46) 46
Romanian (19) 19
Turkish (14) 14
Danish (8) 8
Czech (6) 6
Norwegian (4) 4
Chinese (3) 3
Croatian (3) 3
Dutch (3) 3
Hebrew (2) 2
Slovak (2) 2
Slovenian (2) 2
Swedish (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Finnish (1) 1
Icelandic (1) 1
Korean (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of infection, ISSN 0163-4453, 2014, Volume 69, Issue 3, pp. 216 - 225
Summary Background An intervention for Gram-negative bloodstream infections that integrated mass spectrometry technology for rapid diagnosis with antimicrobial stewardship oversight significantly... 
Infectious Disease | Bloodstream infections | Multidrug resistant | Antimicrobial stewardship | MALDI-TOF | Rapid diagnostics | MORTALITY | ACQUIRED INFECTIONS | INFECTIOUS DISEASES | METAANALYSIS | IDENTIFICATION | DISEASES SOCIETY | IMPACT | THERAPY | HEALTH-CARE | BLOOD-STREAM INFECTIONS | ENTEROBACTERIACEAE | Humans | Middle Aged | Bacteremia - mortality | Male | Pseudomonas Infections - mortality | Gram-Negative Bacterial Infections - microbiology | Time Factors | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Escherichia coli Infections - drug therapy | Escherichia coli - enzymology | Time-to-Treatment | Bacteremia - drug therapy | Klebsiella - enzymology | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas Infections - diagnosis | Survival Rate | Pseudomonas Infections - microbiology | Klebsiella Infections - diagnosis | Gram-Negative Bacterial Infections - diagnosis | Hospital Costs | Escherichia coli Infections - mortality | Pseudomonas aeruginosa - isolation & purification | beta-Lactam Resistance | Acinetobacter Infections - mortality | Klebsiella - isolation & purification | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Resistance, Multiple, Bacterial | Acinetobacter baumannii - isolation & purification | Adult | Female | beta-Lactamases - metabolism | Acinetobacter Infections - microbiology | Length of Stay | Escherichia coli Infections - diagnosis | Intensive Care Units | Klebsiella Infections - drug therapy | Acinetobacter Infections - diagnosis | Hospital Mortality | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Treatment Outcome | Bacteremia - diagnosis | Klebsiella Infections - microbiology | Escherichia coli - isolation & purification | Klebsiella Infections - mortality | Aged | Gram-Negative Bacterial Infections - mortality | Drug resistance in microorganisms | Care and treatment | Mass spectrometry | Patient outcomes
Journal Article
American journal of respiratory and critical care medicine, ISSN 1535-4970, 2016, Volume 193, Issue 5, pp. 504 - 515
Rationale: Cystic fibrosis (CF) is characterized by early structural lung disease caused by pulmonary infections... 
Healthy controls | Cystic fibrosis | Microbiota | Nasopharynx | Longitudinal | microbiota | SMALL-COLONY VARIANTS | CARRIAGE | HAEMOPHILUS-INFLUENZAE | COMMUNITIES | CHILDREN | STREPTOCOCCUS-PNEUMONIAE | INHIBITION | RESPIRATORY SYSTEM | cystic fibrosis | INFLAMMATION | LUNG-DISEASE | STAPHYLOCOCCUS-AUREUS | longitudinal | nasopharynx | healthy controls | CRITICAL CARE MEDICINE | Carrier State - epidemiology | Streptococcus mitis - genetics | Prospective Studies | Humans | Corynebacterium Infections - epidemiology | Carrier State - microbiology | Haemophilus Infections - epidemiology | Infant | Male | Corynebacterium Infections - microbiology | Case-Control Studies | Anti-Bacterial Agents - therapeutic use | Enterobacteriaceae Infections - epidemiology | Female | Staphylococcal Infections - microbiology | Nasopharynx - microbiology | Real-Time Polymerase Chain Reaction | Burkholderia Infections - microbiology | Haemophilus Infections - drug therapy | Infant, Newborn | Staphylococcus aureus - genetics | Moraxellaceae Infections - epidemiology | Streptococcal Infections - microbiology | Burkholderia - genetics | Staphylococcal Infections - drug therapy | Burkholderia Infections - epidemiology | Cystic Fibrosis - microbiology | Enterobacteriaceae Infections - microbiology | Enterobacteriaceae - genetics | Moraxellaceae Infections - microbiology | Streptococcal Infections - epidemiology | Haemophilus influenzae - genetics | Corynebacterium - genetics | Cystic Fibrosis - epidemiology | Moraxellaceae Infections - drug therapy | DNA, Bacterial - genetics | Staphylococcal Infections - epidemiology | Corynebacterium Infections - drug therapy | Microbiota - genetics | Burkholderia Infections - drug therapy | Haemophilus Infections - microbiology | RNA, Ribosomal, 16S - genetics | Streptococcal Infections - drug therapy | Moraxella - genetics | Cohort Studies | Enterobacteriaceae Infections - drug therapy
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2016, Volume 16, Issue 6, pp. 661 - 673
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 1, pp. e0210991 - e0210991
.... Patients with disease- or therapy-related immunodeficiency are especially at risk for fatal infections caused by MDRO... 
HIGH-RISK PATIENTS | IMPACT | THERAPY | RECOMMENDATIONS | NEUTROPENIA | MULTIDISCIPLINARY SCIENCES | HEMATOLOGICAL MALIGNANCIES | BLOOD-STREAM INFECTIONS | KLEBSIELLA-PNEUMONIAE | SOCIETY | ENTEROBACTERIACEAE | Prognosis | Bacterial Infections - etiology | Humans | Middle Aged | Male | Leukemia, Myeloid, Acute - complications | Leukemia, Myeloid, Acute - microbiology | Gram-Negative Bacterial Infections - microbiology | Opportunistic Infections - etiology | Young Adult | Drug Resistance, Multiple, Bacterial | Gram-Positive Bacterial Infections - microbiology | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Retrospective Studies | Staphylococcal Infections - microbiology | Bacterial Infections - microbiology | Intensive Care Units | Staphylococcal Infections - drug therapy | Bacterial Infections - drug therapy | Kaplan-Meier Estimate | Gram-Negative Bacterial Infections - drug therapy | Gram-Positive Bacterial Infections - etiology | Induction Chemotherapy - adverse effects | Opportunistic Infections - microbiology | Vancomycin-Resistant Enterococci - isolation & purification | Opportunistic Infections - drug therapy | Adolescent | Aged | Gram-Negative Bacterial Infections - etiology | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Gram-Positive Bacterial Infections - drug therapy | Staphylococcal Infections - etiology | Drug resistance in microorganisms | Chemotherapy | Usage | Cancer patients | Research | Health aspects | Microbial colonies | Cancer | C-reactive protein | Microbiology | Transplants & implants | Leukemia | Oncology | Drug resistance | Cancer therapies | Subgroups | Proteins | Ethics | CRE bacteria | Neutropenia | Bacterial infections | Hematology | Myeloid leukemia | Mortality | Multidrug resistance | Immunodeficiency | Health risks | Staphylococcus infections | Patients | Disease control | Fever | Medicine | Multidrug resistant organisms | Infectious diseases | Hospitals | Acute myeloid leukemia | Colonization | Index Medicus
Journal Article
BMC infectious diseases, ISSN 1471-2334, 2017, Volume 17, Issue 1, pp. 279 - 13
Background: Drug resistance among gram-negative pathogens is a risk factor for inappropriate empiric treatment (IET... 
Hospital cost | Hospital mortality | Pneumonia | Sepsis | Antimicrobial resistance | UTI | Inappropriate empiric therapy | Enterobacteriaceae | UNITED-STATES | INFECTIOUS DISEASES | SINGLE-CENTER EXPERIENCE | CARE-ASSOCIATED PNEUMONIA | SPECTRUM BETA-LACTAMASE | SEPTIC SHOCK | STAPHYLOCOCCUS-AUREUS | INTERNATIONAL GUIDELINES | ESCHERICHIA-COLI INFECTION | BLOOD-STREAM INFECTIONS | Prevalence | Length of Stay - economics | Humans | Middle Aged | Inappropriate Prescribing - statistics & numerical data | Drug Resistance, Bacterial | Hospitalization - statistics & numerical data | Male | Urinary Tract Infections - economics | Anti-Bacterial Agents - therapeutic use | Enterobacteriaceae Infections - epidemiology | Sepsis - drug therapy | Pneumonia - economics | Aged, 80 and over | Enterobacteriaceae Infections - economics | Inappropriate Prescribing - economics | Adult | Female | Urinary Tract Infections - microbiology | Retrospective Studies | Anti-Bacterial Agents - economics | Sepsis - economics | Hospital Mortality | Pneumonia - epidemiology | Risk Factors | Sepsis - epidemiology | Treatment Outcome | Pneumonia - microbiology | Urinary Tract Infections - drug therapy | Urinary Tract Infections - epidemiology | Health Care Costs | Pneumonia - drug therapy | Carbapenems - therapeutic use | Aged | Carbapenems - economics | Sepsis - microbiology | Enterobacteriaceae Infections - drug therapy | Hospitalization - economics | Drug resistance in microorganisms | Care and treatment | Enterobacteriaceae infections | Bacterial pneumonia | Patient outcomes | Analysis | Urinary tract infections | Research | Carbapenems | Risk factors | Therapy | Antimicrobial activity | Hemodialysis | Communities | Disorders | Urinary tract | Drug resistance | Epidemiology | Antiinfectives and antibacterials | Audio frequencies | CRE bacteria | Classification | Diagnosis | Citrobacter | Pathogens | Preservation | Patients | Disease control | Ertapenem | Urinary tract diseases | Studies | Amplification | Surveillance | Fibrosis | Minimum inhibitory concentration | Death | Adults | Biometrics | Bacilli | Microbiology | Laboratories | Clinical isolates | Risk | Databases | E coli | Cephalosporins | Bacteria | Trends | Children | Urogenital system | Age | Health risks | Staphylococcus infections | Antimicrobial agents | Cystic fibrosis | Hospitalization | Standards | Computer programs | Antibiotics
Journal Article
Antimicrobial agents and chemotherapy, ISSN 1098-6596, 2017, Volume 61, Issue 4
... with a complex molecular background that included , , , , , and combinations thereof. Time-kill assays were conducted, and the efficacy of this combination was assessed in a murine neutropenic thigh infection model... 
Metallo-β-lactamases | Avibactam | Disk diffusion | Ceftazidime | Aztreonam | GRAM-NEGATIVE INFECTIONS | ceftazidime | aztreonam | avibactam | PENICILLIN-BINDING PROTEINS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | TIME | disk diffusion | INHIBITORS | metallo-beta-lactamases | KLEBSIELLA-PNEUMONIAE | Azabicyclo Compounds - pharmacology | Enterobacteriaceae - enzymology | Klebsiella pneumoniae - drug effects | Ceftazidime - pharmacology | Humans | Aztreonam - pharmacology | Colony Count, Microbial | Microbial Sensitivity Tests | Neutropenia - complications | beta-Lactamases - genetics | Neutropenia - microbiology | Klebsiella pneumoniae - genetics | Female | Soft Tissue Infections - drug therapy | beta-Lactamases - metabolism | Drug Therapy, Combination | Neutropenia - chemically induced | Enterobacteriaceae - growth & development | Gene Expression | Klebsiella Infections - drug therapy | Drug Administration Schedule | Enterobacteriaceae Infections - microbiology | Thigh | Enterobacteriaceae - genetics | Klebsiella Infections - complications | Klebsiella Infections - microbiology | Plasmids - metabolism | Neutropenia - drug therapy | Soft Tissue Infections - complications | Cyclophosphamide | Animals | Soft Tissue Infections - microbiology | Enterobacteriaceae - drug effects | Klebsiella pneumoniae - enzymology | Plasmids - chemistry | Klebsiella pneumoniae - growth & development | Anti-Bacterial Agents - pharmacology | Mice | beta-Lactam Resistance - genetics | Enterobacteriaceae Infections - drug therapy | beta-Lactam Resistance - drug effects
Journal Article
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 252 - 257
We determined the incidence, risk factors, and outcomes of bloodstream infections (BSI... 
CLINICAL-PRACTICE GUIDELINES | MORTALITY | AMERICA | OVERGROWTH | VANCOMYCIN | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | COLONIZATION | CRITICALLY-ILL PATIENTS | EUROPEAN-SOCIETY | DISEASES SOCIETY | Coinfection | Humans | Gram-Positive Bacterial Infections - mortality | Bacteremia - mortality | Male | Enterococcus - growth & development | Clostridium Infections - microbiology | Cross Infection - pathology | Gram-Positive Bacterial Infections - microbiology | Candidiasis - pathology | Clostridium Infections - mortality | Odds Ratio | Enterobacteriaceae - growth & development | Enterobacteriaceae Infections - microbiology | Risk Factors | Bacteremia - drug therapy | Cross Infection - drug therapy | Gram-Positive Bacterial Infections - pathology | Candida - pathogenicity | Vancomycin - therapeutic use | Cross Infection - microbiology | Enterobacteriaceae - drug effects | Enterococcus - pathogenicity | Survival Analysis | Clostridium Infections - drug therapy | Enterococcus - drug effects | Gram-Positive Bacterial Infections - drug therapy | Bacteremia - pathology | Clostridium difficile - drug effects | Enterobacteriaceae Infections - drug therapy | Multivariate Analysis | Cross Infection - mortality | Candidiasis - microbiology | Case-Control Studies | Bacteremia - microbiology | Clostridium Infections - pathology | Candidiasis - drug therapy | Metronidazole - therapeutic use | Female | Candida - growth & development | Enterobacteriaceae - pathogenicity | Enterobacteriaceae Infections - mortality | Anti-Infective Agents - therapeutic use | Candidiasis - mortality | Treatment Outcome | Enterobacteriaceae Infections - pathology | Clostridium difficile - pathogenicity | Clostridium difficile - growth & development | Aged | Candida - drug effects
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2012, Volume 55, Issue 7, pp. 943 - 950
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 7, p. e69581
Community-acquired urinary tract infection (CA-UTI) is the most common infection caused by extended-spectrum beta-lactamase (ESBL... 
ESCHERICHIA-COLI STRAINS | NEW-ZEALAND | (ESBL)-PRODUCING ENTEROBACTERIA | MULTIDISCIPLINARY SCIENCES | NONHOSPITALIZED PATIENTS | LACTAMASE-PRODUCING ENTEROBACTERIACEAE | SPECTRUM BETA-LACTAMASES | BLOOD-STREAM INFECTIONS | KLEBSIELLA-PNEUMONIAE | EPIDEMIOLOGY | ONSET | Multivariate Analysis | Demography | Klebsiella pneumoniae - drug effects | Prevalence | Community-Acquired Infections - epidemiology | Escherichia coli - drug effects | Humans | Middle Aged | Male | beta-Lactamases - biosynthesis | Case-Control Studies | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Community-Acquired Infections - drug therapy | Klebsiella pneumoniae - genetics | Female | Urinary Tract Infections - microbiology | Escherichia coli Infections - drug therapy | Escherichia coli - enzymology | Klebsiella Infections - drug therapy | Drug Resistance, Microbial - drug effects | Risk Factors | Escherichia coli Infections - microbiology | Genotype | Logistic Models | Klebsiella Infections - microbiology | Urinary Tract Infections - drug therapy | Escherichia coli Infections - epidemiology | Urinary Tract Infections - epidemiology | Escherichia coli - genetics | Norway - epidemiology | Klebsiella pneumoniae - enzymology | Anti-Bacterial Agents - pharmacology | Community-Acquired Infections - microbiology | Medical research | Medicine, Experimental | Urinary tract infections | Beta lactamases | Diabetes | Behavior | Health aspects | Prevalence studies (Epidemiology) | Fluoroquinolones | Laboratories | Communities | Amdinocillin | Diabetes mellitus | Fish meal | Population studies | Infections | Urinary tract | Risk analysis | Drug resistance | Epidemiology | Risk factors | Confidence intervals | Studies | E coli | Fish | Swimming | Meals | Community medicine, Social medicine: 801 | Samfunnsmedisin, sosialmedisin: 801 | VDP | Basic medical, dental and veterinary science disciplines: 710 | Medical microbiology: 715 | Helsefag: 800 | Health sciences: 800 | Medisinske Fag: 700 | Medisinsk mikrobiologi: 715 | Medical disciplines: 700 | Basale medisinske, odontologiske og veterinærmedisinske fag: 710
Journal Article
by Gutiérrez-Gutiérrez, Belén and Salamanca, Elena and de Cueto, Marina and Hsueh, Po-Ren and Viale, Pierluigi and Paño-Pardo, José Ramón and Venditti, Mario and Tumbarello, Mario and Daikos, George and Cantón, Rafael and Doi, Yohei and Tuon, Felipe Francisco and Karaiskos, Ilias and Pérez-Nadales, Elena and Schwaber, Mitchell J and Azap, Özlem Kurt and Souli, Maria and Roilides, Emmanuel and Pournaras, Spyros and Akova, Murat and Pérez, Federico and Bermejo, Joaquín and Oliver, Antonio and Almela, Manel and Lowman, Warren and Almirante, Benito and Bonomo, Robert A and Carmeli, Yehuda and Paterson, David L and Pascual, Alvaro and Rodríguez-Baño, Jesús and del Toro, M D and Gálvez, J and Falcone, M and Russo, A and Giamarellou, H and Trecarichi, E M and Losito, A R and García-Vázquez, E and Hernández, A and Gómez, J and Bou, G and Iosifidis, E and Prim, N and Navarro, F and Mirelis, B and Skiada, A and Origüen, J and Juan, R San and Fernández-Ruiz, M and Larrosa, N and Puig-Asensio, M and Cisneros, J M and Molina, J and González, V and Rucci, V and de Gopegui, E Ruiz and Marinescu, C I and Martínez-Martínez, L and Fariñas, M C and Cano, M E and Gozalo, M and Mora-Rillo, M and Francisco, C Navarro-San and Peña, C and Gómez-Zorrilla, S and Tubau, F and Tsakris, A and Zarkotou, O and Antoniadou, A and Poulakou, G and Pitout, J and Virmani, D and Torre-Cisneros, J and Guzmán-Puche, J and Helvaci, Ö and Sahin, A O and Pintado, V and Ruiz, P and Bartoletti, M and Giannella, M and Tacconelli, E and Riemenschneider, F and Calbo, E and Badia, C and Xercavins, M and Gasch, O and Fontanals, D and Jové, E and REIPI/ESGBIS/INCREMENT Investigators and REIPI ESGBIS INCREMENT
The Lancet infectious diseases, ISSN 1473-3099, 2017, Volume 17, Issue 7, pp. 726 - 734
Journal Article